key: cord-0710969-8ldm6lv7 authors: Sarkar, Soumya; Kannan, Sundara; Khanna, Puneet; Singh, Akhil Kant title: Role of platelet‐to‐lymphocyte count ratio (PLR), as a prognostic indicator in COVID‐19: A systematic review and meta‐analysis date: 2021-08-31 journal: J Med Virol DOI: 10.1002/jmv.27297 sha: 0eec9ab5616ce5e613fc6640193b1056d9329bde doc_id: 710969 cord_uid: 8ldm6lv7 Prognostic predictors are of paramount interest for prompt intervention and optimal utilization of the healthcare system in the ongoing context of the COVID‐19 pandemic. The platelet‐to‐lymphocyte count ratio (PLR), has emerged as a potential tool for risk stratification of critically ill patients with sepsis. The current systematic review explores the utility of PLR as a prognostic predictor of COVID‐19 patients. We screened the electronic databases until May 15, 2021 after enrolling in PROSPERO (CRD42021220269). Studies evaluating the association between PLR on admission and outcomes in terms of mortality and severity among COVID‐19 patients were included. We retrieved 32 studies, with a total of 2768 and 3262 COVID‐19 patients for mortality and disease severity outcomes. Deceased and critically ill patients had higher PLR levels on admission in comparison to survivors and non‐severe patients (mean differences [MD] = 66.10; 95% confidence interval [CI]: 47.75–84.44; p < 0.00001 and MD = 86.74; 95% CI: 67.7–105.7; p < 0.00001, respectively). A higher level of PLR on admission in COVID‐19 patients is associated with increased morbidity and mortality. However, the evidence is of low quality and further studies regarding the cut‐off value of PLR are the need of the hour. Similarly, inflammation is central to the pathogenesis of COVID-19 and the progress of inflammation or dysfunctional immune response has been associated with severe COVID-19 disease. 7, 8 It is therefore conceivable that patients with a pre-existing chronic inflammatory state will be susceptible to severe COVID-19 disease. In this meta-analysis, we analyzed the studies which had reported PLR on admission and examined the outcome of COVID-19 disease (severity and mortality) and the ability of PLR to predict progression to severe COVID-19 disease. PLR as a marker of pre-existing pro-inflammatory or chronic inflammatory state can be used as a predictor of COVID 19 disease progression. There have been several studies that have examined the relationship between admission PLR and its ability to predict mortality in COVID 19 disease. In this meta-analysis, we aim to systematically analyze the current evidence for the utility of PLR on admission as a prognostic predictor of SARS CoV-2 infection, as per the "Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA-P) guidelines". We prospectively registered the protocol of this systematic review in PROSPERO (ID: CRD42021220269). This study is without any divergence from the reported protocol. Independently, SS, SK, and PK searched the major electronic databases (PubMed, Medline, and Embase), Google Scholar (https://scholar.google.com), preprint platforms MedRxiv (https://www.medrxiv.org), and Clinical trial database (https:// ClinicalTrials.gov) from January 1, 2020 to May 15, 2021 , with the following keywords: "COVID-19" OR "SARS-CoV-2" AND "PLR" OR "Platelet-to-lymphocyte count ratio." SS and PK independently assessed the included studies for any potential bias. The difference of opinion was resolved by consulting with AKS. "The Risk Of Bias In Non-randomized Studiesof Interventions (ROBINS-I)" tool 11 was used for assessing the risk of bias in non-randomized studies. It includes the following seven domains: "bias due to confounding," "selection of participants, classification of interventions," "deviations from intended interventions," "missing data," "measurement of outcomes," and "selection of the reported result." Every domain is graded as "Low," "Moderate," "Serious," and "Critical." Independently PK and SS used the "Grading of Recommendations Assessment, Development and Evaluation (GRADE)" tool, which has five downgrading factors ("study limitations, indirectness, imprecision, consistency of effect, and publication bias") and three upgrading factors ("dose-response relation, large magnitude of the effect, and plausible confounders or biases") 12, 13 for assessing the quality of evidence. Each outcome was graded in terms of either "High" or "Moderate" or "Low" or "Very low". [14] [15] [16] [17] [18] [19] The difference of opinion was resolved with the suggestion of AKS. 20 The I 2 statistic was used for evaluating the statistical heterogeneity, a value of >50% was accepted as significant heterogeneity. Publication bias was assessed with the help of a funnel plot. Thirty-three studies 21-52 out of 979 distinguished publications were incorporated as per the aforementioned inclusion criteria ( Figure 1 and Table 1 ). Twenty-nine articles were peer-reviewed, and three were preprints. 32, 33, 44 ALthough 20 articles evaluated PLR on admission to assess the severity of COVID-19 patients, 14 articles addressed PLR on admission between survivors and non-survivors. Among the included studies, six studies had a moderate degree of bias ( Figure 2 ). The publication bias is represented qualitatively in the Funnel plot ( Figure S1 ). Fourteen articles with a total of 2768 patients were evaluated for mortality in COVID-19. PLR on admission was significantly higher among the deceased in comparison to the survivors (MD = 66.10; 95% CI: 47.75-84.44; I 2 = 89%, p < 0.0001) ( Figure 3 ). Twenty studies with an aggregate of 3262 patients were evaluated for the severity of COVID-19. Critically ill patients are associated with increased PLR on admission (MD = 86.74; 95% CI: 67.7-105.7; Figure 4A ). In subgroup analyses, the baseline PLR was found to be Figure 4D ). We found a low quality of evidence on the impact of raised PLR on COVID-19 mortality and severity (Table 2) . The impact of the baseline PLR on mortality in COVID-19 patients. PLR, platelet-to-lymphocyte count ratio The publication bias was assessed for the studies on COVID-19 mortality. As per the Funnel plot, qualitatively a publication bias is likely in view of some smaller studies with large effects ( Figure S1 ). We have identified low-quality evidence with variability that PLR value on admission has the potential ability of discrimination in COVID-19 patients predicting the mortality and severity. The PLR, a nonspecific inflammatory marker, implies concurrent interaction between platelet count and lymphocyte count, reflects aggregation, as well as inflammatory pathways. It has been found to be elevated in response to many acute as well as chronic proinflammatory conditions [54] [55] [56] and associated with a poor prognosis in patients with COPD 57 and carcinomas. 58-60 A recent study has found a correlation between raised PLR and poor prognosis of sepsisinduced acute kidney injury, and mortality (OR: 1.02, 95% CI: 1.003-1.039). 61 Another recent systematic review 62 also echoed that an elevated PLR is associated with severe illness in COVID-19 patients than in those with mild disease (SMD: 0.68; 95% CI: 0.43-0.93; I 2 = 58%). Although it has been widely acknowledged that both lympho- Our study is one of the extensive and comprehensive systematic reviews of the effectiveness of PLR on admission in patients with COVID-19 for predicting the mortality and severity, and may be considered at the moment as important evidence for decision-making. The majority of the included studies are retrospective in nature and from Asian countries. Although in the current scenario, the prognostic role of PLR in COVID-19 is promising, our findings are heterogeneous, medium in effect, and of low-quality evidence. We also acknowledged that the cut-off value of PLR and the point of evaluation is yet to be standardized, and information in this regard is still evolving. PLR is a potential predictive biomarker for stratifying risk and aiding prompt decisions about an escalation of management, and further large-scale prospective studies in this context are the need of the hour. The authors declare that there are no conflict of interests. Soumya Sarkar: Conceptualization, search strategy, study selection, data extraction, data synthesis, risk of bias assessment, and drafted the manuscript. Sundara Kannan: Study selection and data extraction. Puneet Khanna: Conceptualization, search strategy, study selection, risk of bias assessment, quality of the evidence assessment, and editing. Akhil Kant Singh: Study selection, data extraction, risk of bias assessment, quality of the evidence assessment, and editing. The data that support the findings of this study are available from the corresponding author upon reasonable request. Abbreviations: CI, confidence interval; MD, mean difference. Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were useful markers in assessment of inflammatory response and disease activity in SLE patients The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases Platelet-to-lymphocyte ratio in advanced cancer: review and meta-analysis Platelet-lymphocyte ratio as a potential prognostic factor in gynecologic cancers: a meta-analysis Neutrophil-lymphocyte ratio and plateletlymphocyte ratio as useful predictive markers of prediabetes and diabetes mellitus Prognostic value of neutrophil-tolymphocyte ratio and platelet-to-lymphocyte ratio in acute pulmonary embolism: a systematic review and meta-analysis Immune response, inflammation, and the clinical spectrum of COVID-19 The trinity of COVID-19: immunity, inflammation and intervention The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables The skills and experience of GRADE methodologists can be assessed with a simple tool GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias) GRADE guidelines: 5. Rating the quality of evidence-publication bias GRADE guidelines 6. Rating the quality of evidence--imprecision GRADE guidelines: 7. Rating the quality of evidence--inconsistency GRADE guidelines: 8. Rating the quality of evidence--indirectness GRADE guidelines: 9. Rating up the quality of evidence Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions The systemic inflammation index on admission predicts in-hospital mortality in COVID-19 patients Epicardial adipose tissue, inflammatory biomarkers and COVID-19: Is there a possible relationship? A predicting nomogram for mortality in patients with COVID-19. Front Public Health Comparison of clinical, para-clinical and laboratory findings in survived and deceased patients with COVID-19: diagnostic role of inflammatory indications in determining the severity of illness Hematological parameters predicting severity and mortality in COVID-19 patients of Pakistan: a retrospective comparative analysis The Prognostic Nutritional Index is associated with mortality of COVID-19 patients in Wuhan Ratios of neutrophil-to-lymphocyte and platelet-to-lymphocyte predict all-cause mortality in inpatients with coronavirus disease 2019 (COVID-19): a retrospective cohort study in a single medical centre The neutrophil to lymphocyte ratio and in-hospital all-cause mortality in patients with COVID-19 Can COVID-19 mortality be predicted in the emergency room? Prognostic implications of neutrophil-lymphocyte ratio in COVID-19 Role of neutrophil-to-lymphocyte, lymphocyte-to-monocyte and plateletto-lymphocyte ratios as predictors of disease severity in COVID-19 patients Validity of markers and indexes of systemic inflammation in predicting mortality in COVID 19 infection: a hospital based cross sectional study. medRxiv Paradox of Predictors in Critically ill COVID-19 Patients: Outcome of a COVID-dedicated Intensive Care Unit. medRxiv Clinical profiles, characteristics, and outcomes of the first 100 admitted COVID-19 patients in Pakistan: a single-center retrospective study in a tertiary care hospital of Karachi Clinical and laboratory features of COVID-19: predictors of severe prognosis The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A predictive model for the severity of COVID-19 in elderly patients Novel serological biomarkers for inflammation in predicting disease severity in patients with COVID-19 A tool for early prediction of severe coronavirus disease 2019 (COVID-19): a multicenter study using the risk Nomogram in Wuhan and Guangdong, China Retrospective study of clinical features of COVID-19 in inpatients and their association with disease severity Analysis of hematological indexes of COVID-19 patients from fever clinics in Suzhou, China The role of haematological parameters in patients with COVID-19 and influenza virus infection Associations between hematological parameters and disease severity in patients with SARS-CoV-2 infection Significance of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio for predicting clinical outcomes in COVID-19 Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China Clinical features and potential risk factors for discerning the critical cases and predicting the outcome of patients with COVID-19 Peripheral blood inflammatory markers in predicting prognosis in patients with COVID-19. Some differences with influenza A COVID-19 is distinct from SARS-CoV-2-negative community-acquired pneumonia Evaluation of hematological parameters as an indicator of disease severity in Covid-19 patients: Pakistan's experience Evaluation of the prognostic role of NLR, LMR, PLR and LCR ratio in COVID-19 patients Predictive values of blood urea nitrogen/creatinine ratio and other routine blood parameters on disease severity and survival of COVID-19 patients Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019 Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and platelet to lymphocyte ratio to predict the severity of COVID-19 Is the platelet to lymphocyte ratio a promising biomarker to distinguish acute appendicitis? Evidence from a systematic review with meta-analysis Meta-analysis of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in rheumatoid arthritis Prognostic value of neutrophilto-lymphocyte ratio and platelet-to-lymphocyte ratio in acute pulmonary embolism: a systematic review and meta-analysis Prognostic value of platelet and neutrophil to lymphocyte ratio in COPD patients Elevated serum neutrophil to lymphocyte and platelet to lymphocyte ratios could be useful in lung cancer diagnosis Platelet-to-lymphocyte ratio in advanced cancer: review and meta-analysis Prognostic significance of platelet-tolymphocyte ratio in patients with ovarian cancer: a meta-analysis Relationship between platelet/lymphocyte ratio and prognosis of patients with septic acute kidney injury: a pilot study Platelet-tolymphocyte ratio, a novel biomarker to predict the severity of COVID-19 patients: a systematic review and meta-analysis Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and Meta-analysis Thrombocytopenia is associated with severe coronavirus disease 2019(COVID-19) infections: a metaanalysis Interaction between platelets and endothelium: from pathophysiology to new therapeutic options Emerging roles for platelets as immune and inflammatory cells Inactivation of three emerging viruses severe acute respiratory syndrome coronavirus, Crimean-Congo haemorrhagic fever virus and Nipah virus-in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light Analysis of the level of selected parameters of inflammation,circulating immune complexes,and related indicators (neutrophil/lymphocyte, platelet/lymphocyte, CRP/CIC) in patients with obstructive diseases Integrated clinical, pathologic, virologic, and transcriptomic analysis of H5N1 influenza virusinduced viral pneumonia in the rhesus macaque Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19 High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia Cell Pyroptosis, a Potential Pathogenic Mechanism of 2019-nCoV Infection Hematologic predictors of mortality in hospitalized patients with COVID-19: a comparative study Role of platelet-to-lymphocyte count ratio (PLR), as a prognostic indicator in COVID-19: A systematic review and meta-analysis